RSC-1255 is under clinical development by RasCal Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RSC-1255’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RSC-1255 is under development for the treatment of advanced solid tumor malignancies. It is administered through oral route. It acts by targeting pan-mutant and wild-type RAS.
For a complete picture of RSC-1255’s drug-specific PTSR and LoA scores, buy the report here.